This clinical trial is looking at a new treatment called NBTXR3 combined with radiation therapy. It is for elderly patients who have locally advanced head and neck squamous cell carcinoma. The main goal is to see how well this treatment works and how safe it is compared to radiation therapy alone or with another medicine called cetuximab.
The trial's ID number is NCT04892173. It is a Phase 3 trial, which means it is studying how well the treatment works and its safety. This study is regulated by the FDA and aims to enroll about 500 participants.
Who can join
Participants must be at least 60 years old and have a confirmed diagnosis of squamous cell carcinoma in specific areas of the head and neck. They should be eligible for radiation therapy but cannot receive platinum-based chemotherapy. The trial is open to both men and women. The team will confirm eligibility during the screening process.
Condition
Carcinoma, Squamous Cell
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
People in the trial will be placed into two groups by chance. One group will receive NBTXR3 along with their radiation. The other group will receive just radiation or radiation plus cetuximab. NBTXR3 is given as an injection into the tumor area. Everyone will receive treatment based on the doctor's choice.
Where
This trial is enrolling at 26 locations. Recruiting sites are listed first.
AdventHealth Orlando
Orlando, Florida
Recruiting
Atrium Health Levine Cancer Institute
Charlotte, North Carolina
Recruiting
Boston Medical Center
Boston, Massachusetts
Recruiting
City of Hope
Duarte, California
Recruiting
Emory University Hospital Midtown
Atlanta, Georgia
Recruiting
George Washington University Cancer Center
Washington D.C., District of Columbia
Recruiting
Macon Joan Brock Virginia Health Sciences Eastern Virginia Medical Group at Old Dominion University